GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daewoong Pharmaceutical Co Ltd (XKRX:069620) » Definitions » ROCE %

Daewoong Pharmaceutical Co (XKRX:069620) ROCE % : -2.17% (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Daewoong Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Daewoong Pharmaceutical Co's annualized ROCE % for the quarter that ended in Dec. 2024 was -2.17%.


Daewoong Pharmaceutical Co ROCE % Historical Data

The historical data trend for Daewoong Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daewoong Pharmaceutical Co ROCE % Chart

Daewoong Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.39 3.02 4.58 12.53 5.25

Daewoong Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.94 5.69 14.23 11.28 -2.17

Daewoong Pharmaceutical Co ROCE % Calculation

Daewoong Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=63536.848/( ( (1770310.793 - 695532.72) + (1976977.111 - 629415.584) )/ 2 )
=63536.848/( (1074778.073+1347561.527)/ 2 )
=63536.848/1211169.8
=5.25 %

Daewoong Pharmaceutical Co's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2024 )  (Q: Sep. 2024 )(Q: Dec. 2024 )
=-29659.228/( ( (1922451.914 - 538131.981) + (1976977.111 - 629415.584) )/ 2 )
=-29659.228/( ( 1384319.933 + 1347561.527 )/ 2 )
=-29659.228/1365940.73
=-2.17 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daewoong Pharmaceutical Co  (XKRX:069620) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Daewoong Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Daewoong Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Daewoong Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
12, Bongeunsa-ro 114-gil, Daewoong Pharmaceutical Building, Gangnam-gu, Seoul, KOR
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.

Daewoong Pharmaceutical Co Headlines

No Headlines